921P Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
- Resource Type
- Abstract
- Source
- In
Annals of Oncology September 2020 31 Supplement 4:S665-S665 - Subject
- Language
- ISSN
- 0923-7534